Adrenomed is a German biopharmaceutical company specialized in restoring vascular integrity in life-threatening conditions. The developed pioneering biomarker-guided approach is shifting sepsis treatment towards precision medicine, ensuring that patients get the right drug for their underlying disease mechanism.
Lead product candidate is Adrecizumab. A clinical stage, first-in-class monoclonal antibody that targets the vasoprotective peptide Adrenomedullin, to treat conditions associated with increased vascular leakage, endothelial barrier dysfunction and shock. Lead indication is septic shock.
Improved organ function, reduction of mortality and validation of mode of action has been demonstrated in biomarker guided proof-of-concept Phase II clinical trial (AdrenOSS-2) in 301 septic shock